- Home
- EXLS vs LEGN Comparison
EXLS vs LEGN Comparison
Compare EXLS & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EXLS
- LEGN
- Stock Information
- Founded
- EXLS 1999
- LEGN 2014
- Country
- EXLS United States
- LEGN United States
- Employees
- EXLS N/A
- LEGN N/A
- Industry
- EXLS Business Services
- LEGN Biotechnology: Pharmaceutical Preparations
- Sector
- EXLS Consumer Discretionary
- LEGN Health Care
- Exchange
- EXLS Nasdaq
- LEGN Nasdaq
- Market Cap
- EXLS 7.0B
- LEGN 7.0B
- IPO Year
- EXLS 2006
- LEGN 2020
- Fundamental
- Price
- EXLS $45.64
- LEGN $27.80
- Analyst Decision
- EXLS Strong Buy
- LEGN Strong Buy
- Analyst Count
- EXLS 8
- LEGN 13
- Target Price
- EXLS $49.00
- LEGN $75.67
- AVG Volume (30 Days)
- EXLS 1.6M
- LEGN 1.6M
- Earning Date
- EXLS 04-29-2025
- LEGN 05-13-2025
- Dividend Yield
- EXLS N/A
- LEGN N/A
- EPS Growth
- EXLS 21.21
- LEGN N/A
- EPS
- EXLS 1.32
- LEGN N/A
- Revenue
- EXLS $1,902,884,000.00
- LEGN $728,303,000.00
- Revenue This Year
- EXLS $13.96
- LEGN $65.96
- Revenue Next Year
- EXLS $11.46
- LEGN $52.55
- P/E Ratio
- EXLS $35.48
- LEGN N/A
- Revenue Growth
- EXLS 14.18
- LEGN 112.46
- 52 Week Low
- EXLS $28.59
- LEGN $29.27
- 52 Week High
- EXLS $52.43
- LEGN $60.87
- Technical
- Relative Strength Index (RSI)
- EXLS 48.87
- LEGN 29.31
- Support Level
- EXLS $45.04
- LEGN $30.25
- Resistance Level
- EXLS $48.16
- LEGN $33.30
- Average True Range (ATR)
- EXLS 1.55
- LEGN 1.72
- MACD
- EXLS 0.10
- LEGN -0.41
- Stochastic Oscillator
- EXLS 38.11
- LEGN 3.14
About EXLS ExlService Holdings Inc.
ExlService Holdings Inc. is a business process management company that provides digital operations and analytical services to clients driving enterprise-scale business transformation initiatives that leverage the company's deep expertise in analytics, AI, ML, and cloud. The company offers business process outsourcing and automation services, and data-driven insights to customers across multiple industries. The company operates through four segments based on the products and services offered and markets served: Insurance, Healthcare, Emerging Business, and Analytics . The vast majority of the company's revenue is earned in the United States, and more than half of its revenue comes from Analytics segment.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.